+

WO1996033984A1 - N-sulfoxy anhydrides, a process for the preparation thereof and its use for the preparation of bioactive substances having ace inhibitory action - Google Patents

N-sulfoxy anhydrides, a process for the preparation thereof and its use for the preparation of bioactive substances having ace inhibitory action Download PDF

Info

Publication number
WO1996033984A1
WO1996033984A1 PCT/SI1996/000009 SI9600009W WO9633984A1 WO 1996033984 A1 WO1996033984 A1 WO 1996033984A1 SI 9600009 W SI9600009 W SI 9600009W WO 9633984 A1 WO9633984 A1 WO 9633984A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
preparation
compound
sulfoxy
anhydrides
Prior art date
Application number
PCT/SI1996/000009
Other languages
French (fr)
Inventor
Sonia Serra Mortes
Alberto Palomo Coll
Rok Zupet
Original Assignee
Centro Genesis Para La Investigacion, S.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Genesis Para La Investigacion, S.L. filed Critical Centro Genesis Para La Investigacion, S.L.
Priority to AU52944/96A priority Critical patent/AU5294496A/en
Publication of WO1996033984A1 publication Critical patent/WO1996033984A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D291/00Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/02Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
    • C07D291/04Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • N-sulfoxy anhydrides a process for the preparation thereof and its use for the preparation of bioactive substances having ACE inhibitory action
  • the second type uses e.g. N-[1-(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanyl-N- carboxy-anhydride (NCA; see the formula (II) below) as reactant.
  • NCA N-[1-(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanyl-N- carboxy-anhydride
  • EP 0215335 A2 the reaction of N-[1-(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanine of the formula (I)
  • R 1 represents PhCFH 2 -CH 2 - or CH 3 CH 2 CH 2 - and R 2 represents methyl or R 3 -NH-(CH 2 ) 3 -CH 2 ,-, R 3 being an amino protecting group, preferably CF 3 CO-.
  • the second object of the invention is a process for the preparation of novel N-sulfoxy anhydrides of the formula (III), characterized in that a compound of the formula (IV)
  • R 1 in R 2 have the above meanings
  • R 4 represents the rest of imidazole, of alkyl imidazole, of benzimidazole, of tetrazole and of similar other heterocyclic compounds.
  • the reaction between the compound of the formula (IV) and the compound ot the general formula (V) is carried out in dry organic solvents (humidity ⁇ 0.04% ). preferably in chlorinated organic solvents such as methylene chloride, or non- chlorinated organic solvents such as ethyl acetate, dimethyl carbonate, diethyl carbonate, acetonitrile etc.
  • the formed hydrochloride of a heterocyclic compound e.g. imidazole HCl . methyl- imidazole HCl , benzimidazole HCl , tetrazole HCl etc., is filtered off or sucked ott. Organic bases may be regenerated and recycled.
  • a heterocyclic compound e.g. imidazole HCl . methyl- imidazole HCl , benzimidazole HCl , tetrazole HCl etc.
  • the third object of the invention is a process for the preparation of corresponding ACE inhibitors, wherein NSA (III) is reacted with corresponding derivatives ot amino acids defined below. More particularly, the object of the invention is a process for the preparation of ACE inhibitors of the formula
  • R 1 and R 2 are defined as above and R has the following meanings
  • inorganic salts e.g. potassium or sodium salts are used.
  • organic salts preferably salts of DBU (1.8-diazabicyclo[5.4.0]undec-7-ene).
  • DBN (1,5-diazabicyclo[4.3.0]non-5-ene).
  • TEA triethylamine
  • tetramethylguanidine imidazole. methylimidazole etc. are used.
  • octahydro-1H-indole-2-carboxylic acid a pure isomer is used such as 2S,3aS,7aS or 2S,3aR,7aS, SSS or SRS trandolapril is obtained (see J. Med. Chem. 1987, 30, 992-998).
  • Synthetised ACE inhibitors are recrystallized from acetonitrile or are purified by reprecipitation in ethyl acetate thus achieving high yields at purification (about 94 %).
  • the mother liquor contained the novel compound N-[1-(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanyl-N- sulfoxy- anhydride or NSA, which was analyzed.
  • NSA is oily liquid, unstable in humidity and air. and has a molecular weight 325 determined by iodometric titration on the basis of the following Scheme:
  • NSA thus prepared may be used as starting material for the synthesis of ACE inhibitors.
  • Trimethylchlorosilane (5.7 ml: 0.045 mole) was added to a mixture of L-proline (2.47 g; 0.0215 mole), anhydrous methylene chloride (90 ml) and triethylamine (2.5 ml: 0.018 mole) and the mixture was stirred for 2 hours.
  • Thionylchloride (0.73 ml; 0.01 mole) was added to dry methylene chloride mixture (25 ml: H 2 O ⁇ ⁇ 0.04 % ) and the mixture was cooled to AC. Then imidazole (2.72 g: 0.04 mole) was added. The mixture was stirred for 65 minutes at a temperature between -5°C and room temperature 20°C.
  • opalescent solution A (the preparation thereof is disclosed below) of siiylated (2S.3aS.7aS)- octahydro- 1 H-indole-2-carboxylic acid was added to the filtrate and an opalescent yellow solution was obtained. This solution was stirred for 1 to 6 hours at room temperature (21°C). Then the solution of H 2 O (10 ml) and NaCl (3 g) was added and 35% HCl was added to achieve pH 0.8. It was decanted and the organic phase was washed with water (5 ml). A solution of H 2 O (10 ml) and NaCl (3 g) was added to the organic phase and 33% NaOH was added to achieve pH 4.33.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Novel N-sulfoxy anhydrides, a process for the preparation thereof and its use for the preparation of bioactive substances having ACE inhibitory action. Novel compounds of formula (III), wherein R1 represents PhCH2-CH2- or CH3CH2-CH2- and R2 represents methyl or R3-NH-(CH2)3-CH2-, wherein R3 has the meaning of amino protective group, are disclosed. They are used as intermediates in the synthesis of ACE inhibitors, especially of enalapril and trandolapril.

Description

N-sulfoxy anhydrides, a process for the preparation thereof and its use for the preparation of bioactive substances having ACE inhibitory action
Technical Field
The present invention is from the field of chemical synthesis and relates to novel N-sulfoxy anhydrides, to a process for the preparation thereof as well as to the use thereof for a simple and cheap preparation of bioactive substances having ACE inhibitory action.
Technical Problem
There was a need for a simple and industrially suitable process for the synthesis of active derivative that would be apppropriate as starting material for the synthesis of ACE inhibitors disclosed e.g. in Drugs of the future 1992. 17(7), 551-558. and others.
Prior Art
For the preparation of ACE inhibitors two types of processes are most frequently used. The first one is a reductive amination, which is difficult to be carried out on industrial scale and is disclosed in US 4.374,829.
The second type uses e.g. N-[1-(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanyl-N- carboxy-anhydride (NCA; see the formula (II) below) as reactant. In EP 0215335 A2 the reaction of N-[1-(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanine of the formula (I)
Figure imgf000003_0001
with phosgene and polymers thereof is disclosed and there is obtained N-[ 1-(S)- ethoxycarbonyl-3-phenylpropyl]-L-alanyl-N-carboxy-anhydride (NCA) of the formula (II)
Figure imgf000004_0001
which is reacted with salts and esters of L-proline to enalapril.
The preparation of active NCA is also described in EP 0114067. wherein a reaction of phosgene with amino acid (I) is disclosed. In EP 0061768 Al the preparation of NCA (II) by a reaction of amino acid (I) and carbonyl diimidazole (CDI) is disclosed. The preparation of NCA is also disclosed in ES 2004804. The NCA (II) formed is then reacted with silylated L-proline (YU patent application 1355/88) and with non- silylated L-proline (SI patent 9200213) to enalapril and enalapril maleate, resp., which is an interesting ACE inhibitor.
In all disclosed cases of activation of amino acid (I) there are used toxic phosgene, phosgene polymers (diphosgene. triphosgene) or phosgene derivatives such as CDI, which may be prepared by only a few phosgene producers. The use of CDI for activating amino acid (I) is expensive and it is also necessary to regenerate the waste imidazole. which may be converted again into CDI only by a phosgene producer.
Also in the synthesis of trandolapril disclosed in EP 0088341 and in US 4,490,386, for activating the compound (I) expensive carbonyl diimidazole CDI is used, which is converted into the corresponding NCA (II).
Technical Solution
The first object of the invention are novel N-sulfoxy anhydrides of the formula (III) (NSA)
Figure imgf000004_0002
wherein R1 represents PhCFH2 -CH2- or CH3CH2CH2- and R2 represents methyl or R3-NH-(CH 2) 3-CH2,-, R3 being an amino protecting group, preferably CF3CO-.
The second object of the invention is a process for the preparation of novel N-sulfoxy anhydrides of the formula (III), characterized in that a compound of the formula (IV)
Figure imgf000005_0001
wherein R1 in R2 have the above meanings,
is reacted with an N-(chlorosulfinyl)-heterocyclic compound of the general formula
(V)
Figure imgf000005_0002
wherein R4 represents the rest of imidazole, of alkyl imidazole, of benzimidazole, of tetrazole and of similar other heterocyclic compounds.
Compounds of the general formulas (IV) and (V) are commercially available or may be prepared according to processes known from the literature.
The preparation of the compound of the general formula (V), wherein R4 is an imidazole rest. i.e. chlorosulfinyl imidazole, is disclosed e.g. in Synthetic Communications. 10 ( 10), 733-742. 1980, Masaru Ogata and Hiroshi Matsumato. In the reaction in dry methylene chloride between SOCL, and imidazole in a 1:4 ratio there are obtained N.N'-thionyldiimidazole and imidazole hydrochloride, which is filtered off. An equimolar amount of thionylchloride is added to the filtrate with N.N'-thionyldiimidazole and two molar equivalents of N-chlorosulfinyl imidazole of the formula (V) are obtained. The preparation ot the compound of the general formula (V). wherein R4 is a benzimidazole rest. i.e. N-chlorosulfinyl benzimidazole. is disclosed in Synthetic Communications. 10 (7). 559-567, 1980, Masaru Ogata and Hiroshi Matsumato.
The reaction between the compound of the formula (IV) and the compound ot the general formula (V) is carried out in dry organic solvents (humidity < 0.04% ). preferably in chlorinated organic solvents such as methylene chloride, or non- chlorinated organic solvents such as ethyl acetate, dimethyl carbonate, diethyl carbonate, acetonitrile etc.
The reaction between the compound of the formula (IV) and the compound ot the formula (V) is carried out at a temperature between -15°C and +25°C.
The formed hydrochloride of a heterocyclic compound, e.g. imidazole HCl . methyl- imidazole HCl , benzimidazole HCl , tetrazole HCl etc., is filtered off or sucked ott. Organic bases may be regenerated and recycled.
The pure novel compound of the formula (III) (NSA) remains in the organic solvent. The formation of the compound NSA is confirmed by
a) quantitative isolation of a heterocyclic compound corresponding to the rest R4 in the form of hydrochloride, in two reaction steps;
b) iodometric titration of the amount of SO2 formed after the hydrolysis of NSA; c) IR spectroscopy of the solution of a sample having characteristic absorption bands at 1820 cm-1. 1750 cm-1 in 1030 cm-1;
d) NMR spectra which do not contain signals for protons of the heterocyclic compound (V) used;
e) a turther reaction of NSA with silylated amino acids under release of SO2.
The third object of the invention is a process for the preparation of corresponding ACE inhibitors, wherein NSA (III) is reacted with corresponding derivatives ot amino acids defined below. More particularly, the object of the invention is a process for the preparation of ACE inhibitors of the formula
Figure imgf000006_0001
in racemate form as well as in the form of pure stereoisomers. and pharmaceutically acceptable salts thereof such as hydrochloride, maleinate. sulfate. wherein R1 and R2 are defined as above and R has the following meanings
Figure imgf000007_0001
characterized in that the compound NSA of the formula III is reacted with
a) mono- or disilvlated amino acids or with mixtures of mono- and disilvlated amino acids selected from the group consisting of
Figure imgf000008_0001
at a pH from 2 to 6, preferably 2 to 3, or
b) with inorganic or organic salts of amino acids defined as under a) at a pH over 7, or
c) with a free amino acid defined as under a), preferably with L-proline. and then the obtained compounds are converted in a conventional way into pharmaceutically acceptable salts thereof such as hydrochloride, maleinate, sulfate.
As inorganic salts e.g. potassium or sodium salts are used.
As organic salts preferably salts of DBU (1.8-diazabicyclo[5.4.0]undec-7-ene). DBN (1,5-diazabicyclo[4.3.0]non-5-ene). TEA (triethylamine). tetramethylguanidine. imidazole. methylimidazole etc. are used.
In the case of amino acid N-[ 1-(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanine ( I ) after activation with N-chlorosulfinyl imidazole NSA N-[ 1-(S)-ethoxycarbonyl-3- phenylpropyl]-L-alanyl-N-sulfoxyanhydride is obtained, which is reacted with L-proline. siiylated L-proline or with an organic or inorganic salt ot L-proline to enalapril.
It the same NSA (III) is reacted with a mixture, a silylated mixture or w ith an organic or inorganic salt ot the mixture ot 2S,3aS,7aS- and 2R,3aR,7aR-octahydro- 1 H- indole-2-carboxylic acid, there is obtained a racemic mixture ot SSS and RRR ACE inhibitor having the chemical name 2S,3aS,7aS- or 2R.3aR,7aR-1-{2S-[( 1 R-ethoxy- carbonyl-3-phenylpropyl)amino]-1-oxopropyl }octa-hydro-1H-ιndole-2-carboxylic acid. It as octahydro-1H-indole-2-carboxylic acid a pure isomer is used such as 2S,3aS,7aS or 2S,3aR,7aS, SSS or SRS trandolapril is obtained (see J. Med. Chem. 1987, 30, 992-998).
For the preparation of enalapril the novel compound ot the formula (III) (R1 means PhCH2-CH2-, R2 means methyl), which remains in the organic solvent such as methylene chloride after sucking oft the hydrochloride ot heterocyclic compound such as imidazole hydrochloride and is very reactive, is reacted with siiylated L-proline (process variant a) or with inorganic or organic salt ot L-proline as defined above (process variant b), to N-[1-(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanyl-L- prohne (known as enalapril) with a high yield. During the reaction a gaseous SO2 is released, which also proves the existence ot the novel compound NSA ot formula (III). The reaction between NSA and silylated L-proline is carried out in the temperature range trom -20°C to +25°C. This process is shown in Scheme 1.
In the process variant b) besides the desired ACE inhibitors also novel deriv atives are formed, which in case ot the preparation ot trandolapril have the following formula VII
Figure imgf000009_0001
It may be identified with spectroscopic methods. In the mass spectrum the following signals m/z are present: 692 (M+. 18% ), 431 ( 100% ). 234 (78% ), 170 ( 13% ). 124 (29% ), 91 (35% ).
In the NMR spectrum of the compound VII the ratio between phenyl protons and the proton in position 2 in octahydroindole moiety is 10: 1 and thereby the suggested structure of the compound of the formula (VII) is confirmed.
The use of the compound of the formula (III) as a starting substance makes possible an economical, effective and simple industrial process for the preparation of enalapril. trandolapril and other ACE inhibitors, especially when the process variant a) is used.
The use of NSA is very convenient since the condensation reaction proceeds well already at lower temperatures in the range of from -15°C to + 25°C. Imidazole and other ambident compounds useful in the synthesis of NSA may be isolated quantitatively and recycled. The process is ecologically pure since a major part of reactants may be regenerated and recycled.
Synthetised ACE inhibitors are recrystallized from acetonitrile or are purified by reprecipitation in ethyl acetate thus achieving high yields at purification (about 94 %).
Figure imgf000011_0001
The invention is illustrated but in no way limited by the following Examples.
Example I
Synthesis of N-[ 1-(S)-ethoxycarbonyl-3-phenylprυpyl]-L-alanyl-N-sulfoxy anhydride (NSA. wherein R1 means PhCH2-CH2- and R2 means methyl)
SOCI2 (0.18 ml: 0.0025 mole) was added to anhydrous methylene chloride (7 ml: water content according to Karl Fischer < 0.04%) and the mixture was cooled to -10°C and then imidazole (0.68 g: 0.01 mole) was added. During stirring for 60 minutes the temperature gradually increased to 15°C. The precipitate of imidazole hydrochloride was filtered off. washed with dry CH2Cl2 (5 ml) and a dry salt of imidazole hydrochloride (0.58 g) was obtained. The mother liquor was again cooled to -10°C and thionylchloride (0.18 ml: 0.0025 mole) was added. The solution was stirred for 60 minutes at a temperature between -10°C and +15°C. Then N-[1-(S)-ethoxy- carbonyl-3-phenylpropyl]-L-alanine (1.25 g; 0.0045 mole) and CH2Cl2 (16 ml) was added. After stirring for 65 minutes (the temperature increased from -15°C to +25°C). the precipitate was filtered off, washed with methylene chloride (5 ml) and a dry salt of imidazole hydrochloride (0.51 g) was obtained. After both filtrations imidazole hydrochloride could be regenerated and recycled. The mother liquor contained the novel compound N-[1-(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanyl-N- sulfoxy- anhydride or NSA, which was analyzed. NSA is oily liquid, unstable in humidity and air. and has a molecular weight 325 determined by iodometric titration on the basis of the following Scheme:
Figure imgf000012_0001
2 H2O + SO2 + I2→ 2I- + SO4 2- + 4H+
Excessive I2 was determined by titration with thiosulfate:
L2 + 2 S2O3 2-→ 2I + S4O6 2- IR absorption cm-1
Figure imgf000013_0001
NSA thus prepared may be used as starting material for the synthesis of ACE inhibitors.
Example 2
Synthesis of N-[1-(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanyl-L-proIine maleinate a) Preparation of siiylated L-proline
Trimethylchlorosilane (5.7 ml: 0.045 mole) was added to a mixture of L-proline (2.47 g; 0.0215 mole), anhydrous methylene chloride (90 ml) and triethylamine (2.5 ml: 0.018 mole) and the mixture was stirred for 2 hours. b) Thionylchloride (0.73 ml; 0.01 mole) was added to dry methylene chloride mixture (25 ml: H2O < < 0.04 % ) and the mixture was cooled to AC. Then imidazole (2.72 g: 0.04 mole) was added. The mixture was stirred for 65 minutes at a temperature between -5°C and room temperature 20°C. Then the separated imidazole hydrochloride was filtered off and washed with methylene chloride (5 ml) (the yield of dry imidazole hydrochloride 2.09 g). Thionylchloride (0.73 ml: 0.01 mole) was added to the mother liquor and the mixture was stirred for 60 minutes between -5°C and + 20 °C. The reaction mixture was again cooled to -15°C and N-[ 1-(S)-ethoxy- carbonyl-3-phenylpropyl]-L-alanine (5 g; 0.0179 mole) in methylene chloride (65 ml) was added. The mixture was stirred for 65 minutes and during that time the temperature increased to 20-25°C.
Silylated L-proline was added to the reaction mixture containing only NSA. Acylation was controlled by IR spectroscopy - it was found that -C=O- vibration at 1820 cm-1 disappeared. The reaction was completed in a few hours depending upon reaction temperature. Then the slightly yellowish solution was evaporated on rotavapor and the solvent was removed and water (36 ml). NaCl (12 g) and ethyl acetate ( 18 ml) were added to the residue. The pH 2.66 was changed to pH 4.22 with 33% NaOH. The organic phase was separated and the aqueous phase was extracted twice with ethyl acetate ( 10 ml). The combined ethyl acetate was dried with anhydrous sodium sulfate, sucked off and washed with ethyl acetate (2 x 10 ml) and then methyl acetate (14 ml) was poured thereto. Maleic acid (2.14 g; 0.01844 mole) was added. The mixture was stirred for 20 minutes at room temperature and then for 20 minutes at -25°C. The precipitate formed was filtered off, washed with ethyl acetate and there was obtained enalapril maleate (6.2 g) (yield 88%), m.p. 144-146°C (in the literature 143-144.5°C). [α]20 D 1% MeOH -44.16 (in the literature -42.2).
Example 3
Synthesis of SSS trandolapril
Anhydrous methylene chloride (7 ml) and SOCl2 (0.18 ml; 0.0025 mole) were blended. The solution was cooled to -5°C and imidazole (0.68 g: 0.01 mole ) was added (white suspension). The system was stirred for 1 hour and the temperature was allowed to increase from -5°C to room temperature. Then it was filtered off and solid was washed with CH2Cl2 (5 ml). The liquid was cooled to -5°C and additional SOCl2 (0.18 ml) was added while stirring the system for 1 hour and allowing the temperature to increase from -5°C to room temperature. Then the system was cooled to - 15°C and N-[1-(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanine ( 1.25 g: 0.0045 mole) and anhydrous CH2CI2 (16 ml) were added. The system was stirred for 65 minutes and the temperature was allowed to increase from - 15°C to room temperature. Then it was filtered and the solid was washed with anhydrous CH2Cl2 (5 ml ). An opalescent solution A (the preparation thereof is disclosed below) of siiylated (2S.3aS.7aS)- octahydro- 1 H-indole-2-carboxylic acid was added to the filtrate and an opalescent yellow solution was obtained. This solution was stirred for 1 to 6 hours at room temperature (21°C). Then the solution of H2O (10 ml) and NaCl (3 g) was added and 35% HCl was added to achieve pH 0.8. It was decanted and the organic phase was washed with water (5 ml). A solution of H2O (10 ml) and NaCl (3 g) was added to the organic phase and 33% NaOH was added to achieve pH 4.33. Then it was decanted and the aqueous phase was washed with CH2Cl2 (5 ml). The organic phase was dried with anhydrous Na2SO4, filtered and evaporated on rotavapor. After the evaporation of CH2 Cl2 methyl-tert.-butylether (about 20 ml) was added and it was again evaporated on rotavapor. 2S,3aS,7aS-1 {2S-[(1R-ethoxycarbonyl-3-phenylpropyl)- amino]-1-oxopropyl}octahydro-1-H-indole-2-carboxylic acid (trandolapril base: 1.94 g) was obtained in a 100% yield, m.p. 60°C.
SSS trandolapril
IR: 1755, 1660, 1450, 1220 cm-1
NMR: 7.14-7.32 (m, 5H); 4.46 (t. 1H); 3.95-4.22 (m. 6H): 2.25-2.4 (m. 3H): 2.05 (t.
1H): 1.4-1.85 (m, 5H); 1.31 (d, 3H): 1.23 (t. 3H); 0.9-1.35 (6H)
Mass spectrum: m/z 430 (M+, 2%): 429 (M+ - 1, 14% ): 368 (10): 357 (5): 339 (7):
308 (32); 262 (34); 234 (45); 206 (22); 160 (21): 147 (82): 117 (25); 91 (59); 73 (100); 57 (47).
Elemental analysis for C24H34N2 O5:
%H %C %N
calc: 7.96 66.95 6.51
found: 8.13 66.55 6.31
Preparation of the solution A
(2S.3aS,7aS)-octahydro-1H-indole-2-carboxylic acid (0.90 g; 0.0053 mole ) was blended with anhydrous CH2Cl2 (25 ml), triethylamine (0.73 ml; 0.0053 mole) and (CH3)3 SiCl (0.67 ml: 0.0053 mole). The system was stirred for 1.5 to 2 hours at room temperature (21ºC).
Example 4
Synthesis of SRS trandolapril
It was proceeded in the same way as in Example 3 with the difference that instead of SSS octahydro-1H-indole-2-carboxylic acid, the 2S,3aR,7aS isomer was used. SRS trandolapril 2S,3aR,7aS-1{2S-[(1R-ethoxycarbonyl-3-phenylpropyl)amino]- 1 -oxo- propyl}octahydro-1-H-indole-2-carboxylic acid ( 1.72 g). m.p. 140-143°C. was obtained.
Spectroscopic data:
IR: 1735; 1670; 1450: 1415; 1280 cm-1 mass spectrum (FAB) m/z: 431 (M+ + 1. 52%); 307 (41); 289 (22): 234 (23 ): 154
(100); 137 (89); 120 (18); 107 (27); 89 (25). 77 (21 )
Example 5
Synthesis of trandolapril sulfate
Trandolapril (0.5 g: 0.00116 mole) obtained in Example 3 and methyl-tert.-butyl ether (10 ml) were blended and a yellow solution was obtained. To this solution during 1 hour a sulfuric acid solution (0.5 ml; 0.00036 mole) (this solution was obtained in such a way that 1 ml of 96% sulfuric acid was diluted to 25 ml with methyl- tert.-butyl ether) was added at room temperature (22°C) and under good stirring. In 20 minutes another 0.3 ml (0.000216 mole) of the above sulfuric acid solution were added at - 15°C to -20°C. The system was filtered at -20°C and the solid was washed with methyl-tert.-butyl ether (5 ml) at -20ºC. A beige solid (0.41 g). which was trandolapril sulfate. was obtained with the yield 74.5%. m.p. 86 to 90 ºC. Example 6
Synthesis of trandolapril hydrochloride
Trandolapril (0.5 g; 0.001 16 mole) obtained in Example 3 and methyl-tert.-butyl ether ( 10 ml) were blended and a yellow solution was obtained. This solution was cooled at -15°C to -20°C and HCl gas was bubbled through it. The title product began to precipitate. Since the suspension was very thick, another 3 ml of methyl-tert.-butyl ether was added and HCl gas was bubbled through it (HCl gas was bubbled 5 to 10 minutes in total). The system was stirred at -15°C to -20°C for another 10 minutes and then filtered at this temperature. The solid was washed with methyl-tert.-butyl- ether (5 ml) at -20°C. A beige solid (0.43 g). which was trandolapril hydrochloride. was obtained with the yield 80%, m.p. 105 to 110°C.
Example 7
Synthesis of trandolapril (process variant b)
A racemic mixture (0.9 g; 0.0053 mole) of 2S,3aS,7aS and 2R,3aR,7aR octahydro- 1H-indole-2-carboxylic acid, anhydrous methylene chloride (22 ml) and tetramethyl- guanidine (TMG; 1.56 ml; 0.0124 mole) were blended. The mixture was stirred for 2 hours at 20°C.
To the mother liquor obtained in Example 1 and cooled to -5°C, some 4-N,N- dimethyl aminopyridine was added as a catalyst and the above solution was added drop by drop for 15 minutes at -5°C to 0°C. Then the system was stirred at -5°C to 0°C for 25 minutes and afterwards a solution of H2 O (10 ml) and NaCl (3 g) was added. 1 N HCl was added to achieve pH 4.21 and it was decanted. The aqueous phase was washed with methylene chloride (5 ml) and finally the organic phase was dried with anhydrous sodium sulfate. filtered and evaporated on rotavapor. A yellow solid paste was obtained. Methyl-tert.-butyl ether (15 ml) was added and it was again evaporated on rotavapor. A mixture (2 g) of trandolapril and of the compound of the formula VII was obtained.

Claims

1. N-sulfoxy anhydrides of the formula (III) (NSA)
Figure imgf000018_0001
wherein R1 represents PhCH2-CH2- or CH3CH2CH2 - and R2 represents methyl or R3-NH-(CH2)3-CH2-, R3 being an amino protecting group, preferably CF3CO-.
2. Process for preparing N-sulfoxy anhydrides of the formula (III) according to claim 1, characterized in that a compound of the formula (IV)
Figure imgf000018_0002
wherein R1 in R2 have the above meanings,
is reacted with a N-(chlorosultϊnyl)-heterocyclic compound of the general formula
(V)
Figure imgf000018_0003
wherein R4 represents the rest of imidazole, of alkyl imidazole. of benzimidazole. of tetrazole and of similar other heterocyclic compounds, in dry organic solvents.
3. Process for preparing ACE inhibitors of the formula
Figure imgf000019_0002
in the racemate form as well as in the form of pure stereoisomers, and pharmaceutically acceptable salts thereof such as hydrochloride. maleinate. sulfate, wherein R1 and R2 are defined as in Claim 1 and R has the following meanings
Figure imgf000019_0001
characterized in that the compound NSA of the formula III is reacted with a) mono- or disilylated amino acids or with mixtures of mono- and disilylated amino acids selected from the group consisting of
Figure imgf000020_0001
at a pH from 2 to 6, preferably 2 to 3, or b) with inorganic or organic salts of amino acids defined as under a) at a pH over 7. or c) with a free amino acid defined as under a), preferably with L-proline, and then the obtained compounds are converted in a conventional way into pharmaceutically acceptable salts thereof such as hydrochloride, maleinate, sulfate.
4. Process according to claim 3. characterized in that enalapril and trandolapril are prepared.
5. Process according to claim 3 or 4. characterized in that the synthesized ACE inhibitor is purified by recrystallization from acetonitrile or by reprecipitation in ethyl acetate.
PCT/SI1996/000009 1995-04-24 1996-04-22 N-sulfoxy anhydrides, a process for the preparation thereof and its use for the preparation of bioactive substances having ace inhibitory action WO1996033984A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU52944/96A AU5294496A (en) 1995-04-24 1996-04-22 N-sulfoxy anhydrides, a process for the preparation thereof and its use for the preparation of bioactive substances havi ng ace inhibitory action

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI9500140A SI9500140A (en) 1995-04-24 1995-04-24 Novel n-sulfoxy anhydrides, process for the preparation thereof and its use for the preparation of bioactive substances having ace inhibitory action
SIP-9500140 1995-04-24

Publications (1)

Publication Number Publication Date
WO1996033984A1 true WO1996033984A1 (en) 1996-10-31

Family

ID=20431608

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SI1996/000009 WO1996033984A1 (en) 1995-04-24 1996-04-22 N-sulfoxy anhydrides, a process for the preparation thereof and its use for the preparation of bioactive substances having ace inhibitory action

Country Status (4)

Country Link
AU (1) AU5294496A (en)
CA (1) CA2203435A1 (en)
SI (1) SI9500140A (en)
WO (1) WO1996033984A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1367061A1 (en) * 2003-06-30 2003-12-03 Les Laboratoires Servier Method for synthesis of perindopril and its pharmaceutically acceptable salts
WO2004076417A1 (en) * 2003-02-27 2004-09-10 Hetero Drugs Limited Novel crystalline forms of trandolapril
US7291745B2 (en) 2005-03-21 2007-11-06 Glenmark Pharmaceuticals Limited Process for the preparation of perindopril
US7521566B2 (en) 2003-02-28 2009-04-21 Les Laboratoires Servier Process for preparation of perindopril and salts thereof
US7973173B2 (en) 2005-07-05 2011-07-05 Cipla Limited Process for the synthesis of an ACE inhibitor

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI21703A (en) 2004-01-14 2005-08-31 Lek Farmacevtska Druzba Dd Inclusion complexes of perindopril, procedure of their preparation, pharmaceutical compositions containing these complexes and their application in treatment of hypertensia
SI21881A (en) 2004-10-15 2006-04-30 Diagen, Smartno Pri Ljubljani, D.O.O. New crystal forms of perindopril erbumine hydrates, procedure of their preparation and pharmaceutical forms containing these compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0058567A1 (en) * 1981-02-17 1982-08-25 Warner-Lambert Company Substituted acyl derivatives of octahydro-1H-isoindole-1-carboxylic acids and esters
EP0088341A1 (en) * 1980-10-06 1983-09-14 Warner-Lambert Company Substituted acyl derivative of octahydro-1H-indole-2-carboxylic acid
EP0215335A2 (en) * 1985-08-27 1987-03-25 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Process for preparing N-/1(S)-ethoxycarbonyl-3-phenylpropyl/-L-alanyl-L-proline

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0088341A1 (en) * 1980-10-06 1983-09-14 Warner-Lambert Company Substituted acyl derivative of octahydro-1H-indole-2-carboxylic acid
EP0058567A1 (en) * 1981-02-17 1982-08-25 Warner-Lambert Company Substituted acyl derivatives of octahydro-1H-isoindole-1-carboxylic acids and esters
EP0215335A2 (en) * 1985-08-27 1987-03-25 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Process for preparing N-/1(S)-ethoxycarbonyl-3-phenylpropyl/-L-alanyl-L-proline

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 114, no. 9, 4 March 1991, Columbus, Ohio, US; abstract no. 81985x, LAVAYSSIERE ET AL: "Oxazoliones and dioxolones containing germanium (IV), germanium (II), phosphorus (III), sulfur." page 755; column 1; XP002008602 *
PHOSPHORUS, SULFUR SILICON RELAT. ELEM., vol. 53, no. 1-4, 1990, pages 411 - 422 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076417A1 (en) * 2003-02-27 2004-09-10 Hetero Drugs Limited Novel crystalline forms of trandolapril
US7521566B2 (en) 2003-02-28 2009-04-21 Les Laboratoires Servier Process for preparation of perindopril and salts thereof
EP1367061A1 (en) * 2003-06-30 2003-12-03 Les Laboratoires Servier Method for synthesis of perindopril and its pharmaceutically acceptable salts
WO2005003153A1 (en) * 2003-06-30 2005-01-13 Les Laboratoires Servier Novel method of synthesising perindopril and the pharmaceutically-acceptable salts thereof
US7179833B2 (en) 2003-06-30 2007-02-20 Les Laboratoires Servier Method of synthesising perindopril and the pharmaceutically acceptable salts thereof
EA008836B1 (en) * 2003-06-30 2007-08-31 Ле Лаборатуар Сервье Novel method of synthesising perindopril and the pharmaceutically-acceptable salts thereof
AU2004253721B2 (en) * 2003-06-30 2007-12-20 Les Laboratoires Servier Novel method of synthesising perindopril and the pharmaceutically-acceptable salts thereof
US7291745B2 (en) 2005-03-21 2007-11-06 Glenmark Pharmaceuticals Limited Process for the preparation of perindopril
US7973173B2 (en) 2005-07-05 2011-07-05 Cipla Limited Process for the synthesis of an ACE inhibitor

Also Published As

Publication number Publication date
AU5294496A (en) 1996-11-18
CA2203435A1 (en) 1996-10-31
SI9500140A (en) 1996-10-31

Similar Documents

Publication Publication Date Title
KR890002104B1 (en) Method for preparing 4-substituted-2-azetidinone compound
CA1205476A (en) Substituted acyl derivatives of octahydro-1h-indole-2- carboxylic acids
FR2663336A1 (en) NOVEL PEPTIDE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
HUT68200A (en) Process for producing peptides inhibiting il-1-beta release and pharmaceutical compositions containing them as active component
ES2371699T3 (en)  NEW DIAZENIO DIOLATE DERIVATIVES, ITS PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US5359086A (en) Process for preparing alkyl-L-alanyl-L-proline derivatives
WO1996033984A1 (en) N-sulfoxy anhydrides, a process for the preparation thereof and its use for the preparation of bioactive substances having ace inhibitory action
US4537714A (en) Process for the preparation of lower alkyl esters of N-L-α-aspartyl-L-phenylalanine and of new intermediates for their preparation
EP0285992B1 (en) Crystalline quinapril and a process for producing the same
EP1371659B1 (en) Method for synthesis of perindopril and its pharmaceutically acceptable salts [2003/26]
JPS6332073B2 (en)
US4761495A (en) Method relating to preparation of aspartyl peptides
SU1375123A3 (en) Method of producing n-substituted l-amino acids
SI21704A (en) New crystal form of perindopril, procedure of its preparation, pharmaceutical preparations containing this form and their application in treatment of hypertensia
US5789597A (en) Process for the preparation of compounds having ACE inhibitory action and intermediates in said process
EP0839128B1 (en) Process for the preparation of ethyl 3s-[[4-[[4-(aminoiminomethyl)phenyl]amino]-1,4-dioxobutyl]amino]-4-pentynoate
HU188177B (en) Process for producing new proline derivatives
EP0015773A2 (en) N-(6-((acylaminoacylamino or aminoacylamino)phenyl) 1,2-dihydro-2-oxonicotinyl)penicillin compounds, processes for their production and compositions containing them
WO2001040263A1 (en) 1,3,4-oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient
HU222843B1 (en) Nalpha-2-(4-nitrophenylsulfonyl)ethoxycarbonyl-amino acids and process for production them
US5126451A (en) Renin inhibitors containing α-heteroatom amino acids
KR100273765B1 (en) Method for preparing N- (4-piperidine) benzamide and new active thioester as an intermediate thereof and method for preparing same
US6063962A (en) Process for the preparation of NMDA antagonists
US5962722A (en) α-hydrazino acid derivatives and method for making same
HU185953B (en) Process for producing new 4.cabamoyloxy-oxaza-phosphorines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: US

Ref document number: 1997 817298

Date of ref document: 19970415

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref document number: 2203435

Country of ref document: CA

Ref country code: CA

Ref document number: 2203435

Kind code of ref document: A

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载